Curated News
By: NewsRamp Editorial Staff
August 18, 2026
NanoViricides to Launch Ebola Drug Trial in Congo
TLDR
- NanoViricides advances NV-387 for Ebola, gaining regulatory approval and first-mover advantage in DRC clinical trials.
- NV-387 oral gummies mimic host factors to block viral entry, now entering Phase II in DRC with CRO Om Sai Clinical Research.
- Oral antiviral for Ebola could simplify treatment in remote outbreaks, potentially saving more lives with easier administration.
- NanoViricides' Ebola drug is an oral gummy, a novel format for antiviral therapy, and trials are set to begin soon.
Impact - Why it Matters
This news is significant because it represents a major step forward in the fight against Ebola, a deadly virus that has caused numerous outbreaks in Africa. If successful, NV-387 could provide a much-needed oral treatment that is easier to administer in remote areas, potentially saving countless lives. Additionally, the same drug candidate is being tested for Mpox, another emerging threat, highlighting the versatility and broad-spectrum potential of NanoViricides' technology. For investors, this trial could be a catalyst for the company's growth, as positive results would validate its platform and open doors to regulatory approvals.
Summary
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage biopharmaceutical company specializing in antiviral therapies, has announced that its Phase II clinical trial for NV-387 Oral Gummies to treat Ebola virus infections is set to commence in the Democratic Republic of Congo (DRC). The company has secured regulatory approval from the local agency ACOREP and has appointed Professor Patrick Katoto as the principal investigator. Preparatory activities, including staff training, are already underway, and the drug product is available in the DRC, with the first patient dosing expected within weeks, barring any outbreak-related delays.
NV-387 is an orally administered broad-spectrum antiviral designed to mimic host-cell features that viruses exploit for infection. The company believes that an oral formulation offers significant advantages in resource-limited settings compared to intravenous treatments. Om Sai Clinical Research Private Limited will serve as the contract research organization (CRO) for this trial and also for the planned Phase II trial of NV-387 for Mpox in the DRC. This development underscores NanoViricides' commitment to addressing urgent global health threats, particularly in regions with limited healthcare infrastructure.
For more details, the full press release can be accessed at https://ibn.fm/uWVTo. NanoViricides, based on its proprietary nanoviricide technology, is also developing treatments for other viral diseases, including COVID-19, influenza, and herpes. The company's mission is to provide effective and accessible antiviral therapies, and this trial marks a significant milestone in that journey.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides to Launch Ebola Drug Trial in Congo
